What is Lifesci Capital’s Forecast for SLNO Q3 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Research analysts at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for Soleno Therapeutics in a research report issued on Wednesday, September 10th. Lifesci Capital analyst K. Dellorusso anticipates that the company will earn ($0.01) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.63 EPS, Q4 2026 earnings at $0.91 EPS and FY2026 earnings at $2.91 EPS.

A number of other research analysts have also recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $110.00 price target (up from $100.00) on shares of Soleno Therapeutics in a research note on Monday, August 18th. Robert W. Baird set a $121.00 price target on Soleno Therapeutics and gave the company an “outperform” rating in a research note on Friday, July 11th. Oppenheimer increased their price target on Soleno Therapeutics from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 7th. TD Cowen assumed coverage on Soleno Therapeutics in a research note on Monday, June 23rd. They issued a “buy” rating and a $110.00 price target for the company. Finally, Wells Fargo & Company initiated coverage on Soleno Therapeutics in a research note on Wednesday, August 20th. They issued an “overweight” rating and a $123.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $115.09.

Soleno Therapeutics Stock Down 5.5%

Shares of SLNO opened at $53.62 on Friday. Soleno Therapeutics has a 52 week low of $41.50 and a 52 week high of $90.32. The stock has a market capitalization of $2.85 billion, a price-to-earnings ratio of -12.95 and a beta of -2.72. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13. The stock has a fifty day moving average of $77.05 and a 200-day moving average of $71.64.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.44. The business had revenue of $32.66 million for the quarter, compared to the consensus estimate of $3.91 million.

Insider Transactions at Soleno Therapeutics

In related news, insider Patricia C. Hirano sold 3,830 shares of the firm’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the transaction, the insider directly owned 13,206 shares of the company’s stock, valued at $1,092,928.56. This trade represents a 22.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SLNO. Northern Trust Corp raised its position in shares of Soleno Therapeutics by 17.8% in the 4th quarter. Northern Trust Corp now owns 226,889 shares of the company’s stock worth $10,199,000 after acquiring an additional 34,309 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Soleno Therapeutics by 25.9% in the 4th quarter. Ameriprise Financial Inc. now owns 35,106 shares of the company’s stock worth $1,578,000 after acquiring an additional 7,223 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Soleno Therapeutics in the 4th quarter worth about $3,206,000. Deutsche Bank AG raised its position in shares of Soleno Therapeutics by 44.8% in the 4th quarter. Deutsche Bank AG now owns 119,455 shares of the company’s stock worth $5,370,000 after acquiring an additional 36,971 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in shares of Soleno Therapeutics by 95.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 9,201 shares of the company’s stock worth $414,000 after acquiring an additional 4,500 shares in the last quarter. 97.42% of the stock is owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.